US4940730A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Angiogenesis enhancer
Assignee: Takeda Pharmaceutical Co Ltd
•
Filing: 1988-10-03
•
Granted: 1990-07-10
•
Expires: 2008-10-03
Abstract
Abstract The present invention relates to a composition with enhanced angiogenic activity which contains a compound of the formula: R--A wherein R stands for a higher aliphatic hydrocarbon residue, and A stands for hydrogen atom, carboxyl group, hydroxyl group, carbamoyl group which may be substituted or amino group which may be substituted or quaternized. The composition of the present invention has been found to enhance blood vessel formation, which is useful for the treatment of various ischemic diseases, trauma, thermal burns, alopecia, etc.
Inventors
- 👤 Kaori Wakamatsu
- 👤 Koichi Kondo
- 👤 Katsuichi Sudo
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 18:19
CPC Classifications
C; C07; C07D; C07D295/00; C07D295/16; C07D295/18; C07D295/182; C07D295/185; A; A61; A61K; A61K31/00; A61K31/16; A61K31/21; A61K31/215; A61K31/22; A61K31/23; A61K31/235; A61K31/24; A61K31/245; A61K31/33; A61K31/335; A61K31/395; A61K31/40; A61K31/403; A61K31/404; A61K31/405; A61K31/41; A61K31/425; A61K31/435; A61K31/44; A61K31/445; A61K31/535; C07C; C07C233/00; C07C233/01; C07C233/02; C07C233/09; C07C233/16; C07C233/17; C07C233/20; C07C233/45; C07C233/46; C07C233/49; C07C233/53; C07C233/55; C07C235/00; C07C235/02; C07C235/04; C07C235/06; C07D207/00; C07D207/02; C07D207/04; C07D207/10; C07D207/16; C07D417/00; C07D417/02; C07D417/04
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
32 words
[The] A composition [according to claim 10, wherein] with enhanced angiogenic activity which contains an effective amount of the compound [is] erucamide[.], together with a physiologically acceptable carrier, excipient, or diluent therefor.
Claim 2
Dependent Claim
33 words
[The] A composition [according to claim 10, wherein] with enhanced angiogenic activity which contains an effective amount of the compound [is] N-erucoyl-3-aminobenzoic acid[.], together with a physiologically acceptable carrier, excipeint, or diluent therefor.
Claim 3
Dependent Claim
26 words
A composition with enhanced angiogenic activity which contains an effective amount of the compound erucic acid, together with a physiologically acceptable carrier, excipient, or diluent therefor.
Claim 4
Dependent Claim
26 words
A composition with enhanced angiogenic activity which contains an effective amount of the compound erucic acid, together with a physiologically acceptable carrier, excipient, or diluent therefor.
Claim 5
Dependent Claim
25 words
A composition with enhanced angiogenic activity which contains an effective amount of the compound brassidamide, together with a physiologically acceptable carrier, excipient, or diluent therefor.
Claim 6
Dependent Claim
25 words
A composition with enhanced angiogenic activity which contains an effective amount of the compound brassidamide, together with a physiologically acceptable carrier, excipient, or diluent therefor.
References Cited (Backward Citations)
US3219659A
Cited
WO1986001111A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-07-09 | 1994-01-08 | 1994-07-10 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-07-09 | 1998-01-08 | 1998-07-10 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-07-09 | 2002-01-08 | 2002-07-10 | $7700.00 | Window Closed / Lapsed |